title: Recent developments in the treatment of otitis media with effusion.
abstract: The management of otitis media with effusion (OME) has received much attention recently as a result of, among other factors, the development of resistant bacteria and the finding of less long-term impact of middle-ear effusion (MEE) on development than previously believed. Guidelines have recently been published for the management of OME promoting more accurate diagnosis, particularly distinguishing acute otitis media from OME, and recommending the 'judicious' use of antibacterials. Today, more emphasis is being placed on prevention of disease by reducing risk factors and the development of vaccines. The identification of susceptibility genes may lead to better understanding of the pathogenesis of otitis media, which in turn may lead to the development of more innovative and satisfactory methods for prevention and treatment.
authors.affiliation: ENT Research Center, Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania 15213, USA. mandele@pitt.edu
authors.forename: Ellen M
authors.initials: EM
authors.lastname: Mandel
authors.forename: Margaretha L
authors.initials: ML
authors.lastname: Casselbrant
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D003937:Diagnosis, Differential; D006634:Histamine H1 Antagonists / Q000627:therapeutic use*; D006801:Humans; D007223:Infant; D009225:Myringoplasty / Q000379:methods*; D014663:Nasal Decongestants / Q000627:therapeutic use*; D009998:Ossicular Prosthesis; D010034:Otitis Media with Effusion / Q000175:diagnosis / Q000188:drug therapy* / Q000601:surgery; D011788:Quality of Life; D016032:Randomized Controlled Trials as Topic
chemical_list: D000900:Anti-Bacterial Agents; D006634:Histamine H1 Antagonists; D014663:Nasal Decongestants